• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What Disc Medicine (IRON)'s Phase 3 Trial Success Means For Shareholders

    Simply Wall St·11/06/2026 16:24:49
    Listen to the news
    • Disc Medicine reported third quarter 2026 results with a net loss of US$59.54 million and basic and diluted loss per share of US$1.53, alongside confirming that the pivotal Phase 3 APOLLO trial of bitopertin in erythropoietic protoporphyria met all primary and secondary endpoints.
    • The successful APOLLO Phase 3 outcome gives Disc Medicine a clearer regulatory path for bitopertin, which could shift the business mix over time from a pure R&D story toward a potential commercial rare disease portfolio if regulatory approvals are obtained.
    • This article now examines how Disc Medicine's investment narrative could be reshaped by the APOLLO Phase 3 results for bitopertin in EPP.

    Scan beyond Disc Medicine for other rare disease and hematology opportunities by reviewing the hand-picked 21 high quality undiscovered gems, which are also trying to turn focused R&D into future product portfolios.

    Disc Medicine Investment Narrative Recap

    To own Disc Medicine, you need to believe this is primarily a regulatory and execution story in rare blood disorders, not an earnings story yet. The third quarter net loss of US$59.54 million and loss per share of US$1.53 underline that the business is spending heavily with effectively no revenue. The key near term swing factor is whether regulators accept the APOLLO data for bitopertin after the earlier Complete Response Letter, since any delay would likely remain the biggest operational risk.

    The successful Phase 3 result improves the setup for that resubmission but does not change that Disc Medicine is still loss making and forecast to stay unprofitable for several years. Cash of roughly US$730 million at the end of the second quarter of 2026 gives the group room to fund bitopertin launch preparations and move selcodebart and DISC-3405 forward, although persistent losses and any legal costs from the ongoing securities investigations could strain that flexibility over time.

    The recent update that Disc Medicine plans to resubmit the bitopertin NDA by the end of 2026, targeting an FDA decision around mid 2027, appears most directly tied to the current news. APOLLO’s clean outcome gives management a basis to argue that prior regulatory concerns around evidence have been addressed. For you, that filing timeline effectively sets the main catalyst clock, since bitopertin is positioned as the first potential commercial product.

    That same announcement also framed selcodebart in myelofibrosis anemia and DISC-3405 in polycythemia vera as follow on drivers, with Phase 2 data feeding into planned FDA interactions and potential pivotal designs. If bitopertin moves forward as planned, those programs could matter more for how investors think about duration of losses, operating leverage and whether Disc Medicine can evolve from a single asset bet into a broader rare disease platform.

    Disc Medicine’s narrative projects US$283.9 million revenue and US$51.9 million earnings by 2029. This assumes revenue grows from effectively zero today to that level over roughly three years, and requires an earnings swing of about US$297.8 million from current losses of US$245.9 million.

    Uncover why Disc Medicine's fair value indicates a 60% potential upside to its current price before that valuation gap starts to close.

    NasdaqGM:IRON 1-Year Stock Price Chart
    NasdaqGM:IRON 1-Year Stock Price Chart

    Exploring Other Perspectives

    One alternate view focuses on bitopertin uptake rather than just FDA timing. Bullish analysts were already pencilling in US$379.0 million of revenue and US$60.6 million of earnings by 2029 for Disc Medicine, compared with consensus at US$283.9 million and US$51.9 million. Those pre news projections could shift if investors reassess real world demand after the APOLLO result.

    Explore another Disc Medicine fair value estimate, including one that suggests there may be as much as 60% upside from the current price.

    Form Your Own Verdict

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    Looking For More Investment Ideas Beyond Disc Medicine?

    Once you have formed a view on Disc Medicine, it can help to compare that thesis with other opportunities that share similar traits, whether you care most about value, resilience, or income. The Simply Wall St Screener gives you a structured way to do that, so you are not just relying on headlines or hunches.